Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - MERRIMACK PHARMACEUTICALS INC | mack-ex322_15.htm |
| EX-32.1 - EX-32.1 - MERRIMACK PHARMACEUTICALS INC | mack-ex321_10.htm |
| EX-31.2 - EX-31.2 - MERRIMACK PHARMACEUTICALS INC | mack-ex312_8.htm |
| EX-31.1 - EX-31.1 - MERRIMACK PHARMACEUTICALS INC | mack-ex311_7.htm |
| EX-21.1 - EX-21.1 - MERRIMACK PHARMACEUTICALS INC | mack-ex211_11.htm |
| EX-10.23 - EX-10.23 - MERRIMACK PHARMACEUTICALS INC | mack-ex1023_791.htm |
| EX-10.11 - EX-10.11 - MERRIMACK PHARMACEUTICALS INC | mack-ex1011_790.htm |
| EX-4.1 - EX-4.1 - MERRIMACK PHARMACEUTICALS INC | mack-ex41_792.htm |
| 10-K - 10-K - MERRIMACK PHARMACEUTICALS INC | mack-10k_20171231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (No. 333-222093) and S-8 (Nos. 333-180996, 333-186370, 333-194313, 333-202346 and 333-209745) of Merrimack Pharmaceuticals, Inc. of our report dated March 12, 2018 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 12, 2018